16:09:26 EDT Tue 29 Sep 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 21,238,831
Close 2019-03-08 C$ 0.98
Recent Sedar Documents

Trillium closes public offering for $15-million (U.S.)

2019-03-08 18:42 ET - News Release

Mr. James Parsons reports

TRILLIUM ANNOUNCES CLOSING OF US$15 MILLION PUBLIC OFFERING OF COMMON SHARE UNITS AND SERIES II NON-VOTING CONVERTIBLE FIRST PREFERRED SHARE UNITS

Trillium Therapeutics Inc. has closed its previously announced underwritten public offering of 6.55 million common share units of the company and 12.2 million Series 2 non-voting convertible first preferred share units of the company.

The common share units were sold at a public offering price of 80 U.S. cents per common share unit. Each common share unit is composed of one common share of the company and one common share purchase warrant. Each common share warrant is exercisable for one common share at a price of 96 U.S. cents per common share warrant, subject to adjustment, at any time until 5 p.m. Toronto time on Feb. 28, 2024, subject to certain terms and conditions. The Series 2 first preferred share units were sold at a public offering price of 80 U.S. cents per Series 2 first preferred share unit. Each Series 2 first preferred share unit is composed of one Series 2 non-voting convertible first preferred share and one Series 2 first preferred share purchase warrant. Each Series 2 first preferred share warrant is exercisable for one Series 2 first preferred share at a price of 96 U.S. cents per Series 2 first preferred share warrant, subject to adjustment, at any time until 5 p.m. Toronto time on Feb. 28, 2024, subject to certain terms and conditions.

The gross proceeds to the company from the offering were $15-million (U.S.) before deducting underwriting discounts and commissions and other expenses of the offering.

The company intends to use the net proceeds of the offering for: (i) continuing research and development activities of its SIRPaFc program; and (ii) working capital and general corporate purposes.

Cowen and Company LLC acted as the sole book-running manager for the offering.

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a do-not-eat signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds, directed at undisclosed immuno-oncology targets.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.